Results 271 to 280 of about 305,738 (309)
Some of the next articles are maybe not open access.
DNA Clutch Probes for Circulating Tumor DNA Analysis
Journal of the American Chemical Society, 2016Progress toward the development of minimally invasive liquid biopsies of disease is being bolstered by breakthroughs in the analysis of circulating tumor DNA (ctDNA): DNA released from cancer cells into the bloodstream. However, robust, sensitive, and specific methods of detecting this emerging analyte are lacking. ctDNA analysis has unique challenges,
Jagotamoy, Das +3 more
openaire +2 more sources
Circulating Tumor Cells and Circulating Tumor DNA in Colorectal Cancer
Expert Review of Precision Medicine and Drug Development, 2016ABSTRACTGenetic alterations in cancers serve as useful biomarkers in evaluating diagnosis, prognosis, and therapeutics. Genotyping tumour biopsies has become a routine practice in clinical oncology; however, it can only provide a spatially and temporally limited snapshot of the tumour achieved through an invasive procedure at a single time point ...
Nur-Afidah Mohamed Suhaimi, Min-Han Tan
openaire +1 more source
Advances in Circulating Tumor DNA Analysis
2017The analysis of cell-free circulating tumor DNA (ctDNA) is a very promising tool and might revolutionize cancer care with respect to early detection, identification of minimal residual disease, assessment of treatment response, and monitoring tumor evolution.
Samantha, Perakis +3 more
openaire +2 more sources
NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA
2023Accurate circulating tumor DNA (ctDNA) detection has an immense biomarker potential in all phases of the cancer disease course. Presence of ctDNA in the blood has been shown to have prognostic value in various cancer types as it may reflect the actual tumor burden.
Nordentoft, Iver +2 more
openaire +3 more sources
Liquid Biopsy in Breast Cancer: Circulating Tumor Cells and Circulating Tumor DNA
2021Cancer is associated with gene mutations, and the analysis of tumor-associated mutations is increasingly used for diagnostic, prognostic, and treatment purposes. These molecular landscapes of solid tumors are currently obtained from surgical or biopsy specimens.
openaire +2 more sources
Circulating tumor DNA analysis of neuroendocrine tumors.
Journal of Clinical Oncology, 2019e15698 Background: Neuroendocrine tumors (NETs) and carcinomas (NECs) are a diverse group of tumors with an equally diverse biology and clinical behavior. Data on tissue-based genomic profiling of NETs exists, however, there is limited data using circulating tumor DNA (ctDNA) technology.
Jason Scott Starr +3 more
openaire +1 more source
Circulating tumor DNA—From bench to bedside
Current Problems in Cancer, 2017In the era of personalized medicine, tumor sampling is paramount to enable the assessment of actionable molecular aberrations to help rationalize and guide treatment decisions. Longitudinal tracking of such aberrations may also be helpful to detect emerging drug resistance and to allow for timely modifications to ongoing therapies to improve patient ...
Lim, JSJ, Janku, F, Yap, TA
openaire +3 more sources
Epigenomic technologies for deciphering circulating tumor DNA
Current Opinion in Biotechnology, 2019Tumor-derived DNA, found in body fluids (liquid biopsy) of cancer patients as part of cell-free DNA (cfDNA), lends itself for noninvasive cancer detection and monitoring. Advantages of cfDNA as analytical target have evoked a burst of sophisticated techniques, providing clinically relevant information.
Kristina, Daniūnaitė +2 more
openaire +2 more sources
Detecting cancer by monitoring circulating tumor DNA
Nature Medicine, 2014DNA that is shed by dead tumor cells into the blood, termed circulating tumor DNA (ctDNA), is a rich resource that could potentially be used for cancer diagnostics and monitoring. A new study describes a sequencing-based method that improves upon the sensitivity and specificity achieved by past techniques for detecting ctDNA and that can be used for ...
Paul T, Spellman, Joe W, Gray
openaire +2 more sources
Circulating Tumor DNA: Measurement and Clinical Utility
Annual Review of Medicine, 2018Circulating tumor DNA (ctDNA) is a component of the “naked” DNA found in blood. It can be isolated from plasma and represents combined genetic material from the primary tumor and metastases. Quantitative and qualitative information about a cancer, including mutations, can be derived using digital polymerase chain reaction and other technologies. This “
Joshua, Donaldson, Ben Ho, Park
openaire +2 more sources